Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 5/20 | 0.64 |
| ▸ | LAP3 | P28838 | 2/20 | 0.59 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.52 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.52 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.52 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.50 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.50 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5745776 | 1.00 | FDPS (0.64) | FDPSLAP3S1PR2S1PR1S1PR3 | |
| SCHEMBL2251269 | 0.98 | FDPS (0.65) | FDPSLAP3S1PR2S1PR1S1PR3 | |
| SCHEMBL2254762 | 0.98 | FDPS (0.65) | FDPSLAP3S1PR2S1PR1S1PR3 | |
| SCHEMBL2255133 | 0.98 | FDPS (0.65) | FDPSLAP3S1PR2S1PR1S1PR3 | |
| SCHEMBL629521 | 0.98 | FDPS (0.65) | FDPSLAP3S1PR2S1PR1S1PR3 | |
| SCHEMBL10876126 | 0.98 | FDPS (0.65) | FDPSLAP3S1PR2S1PR1S1PR3 | |
| SCHEMBL2250970 | 0.98 | FDPS (0.65) | FDPSLAP3S1PR2S1PR1S1PR3 | |
| SCHEMBL2254314 | 0.98 | FDPS (0.65) | FDPSLAP3S1PR2S1PR1S1PR3 | |
| SCHEMBL1259333 | 0.98 | FDPS (0.65) | FDPSLAP3S1PR2S1PR1S1PR3 | |
| SCHEMBL6433185 | 0.98 | FDPS (0.65) | FDPSLAP3S1PR2S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118847375-A | Flotation reagent and method for carrying out flotation separation on micro-fine cassiterite and magnesium-containing gangue minerals | 中南大学 | 2024-10-29 | — | — | CN | claimed |
| CN-118847375-A | Flotation reagent and method for carrying out flotation separation on micro-fine cassiterite and magnesium-containing gangue minerals | 中南大学 | 2024-10-29 | — | — | CN | disclosed |
| US-20120108533-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-05-03 | — | — | US | disclosed |
| EP-2424874-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL ANGENTS | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010125200-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL ANGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2010-11-04 | — | — | WO | disclosed |
| EP-0826652-B1 | PROCESS FOR PREPARING ASYMMETRIC COMPOUND BY USING METAL COMPLEX | NAGASE & CO LTD (JP) | 2006-09-06 | — | — | EP | disclosed |
| US-6090969-A | REACTING AN OPTICALLY ACTIVE BINAPHTHOL WITH AN ALKALI METAL ALUMINUM HYDRIDE OR A DIALKYLALUMINUM HYDRIDE AND AN ALKALI OR ALKALINE EARTH METAL BASE | NAGASE AND CO., LTD. (JP) | 2000-07-18 | — | — | US | disclosed |
| US-5847186-A | Process for preparing asymmetric compound by using metal complex | NAGASE & COMPANY, LTD. (JP) | 1998-12-08 | — | — | US | disclosed |
| CN-1182412-A | Process for preparing asymmetric compound by using metal complex | NAGASE & CO LTD (JP) | 1998-05-20 | — | — | CN | disclosed |
| EP-0826652-A1 | PROCESS FOR PREPARING ASYMMETRIC COMPOUND BY USING METAL COMPLEX | NAGASE & COMPANY, LTD. (JP) | 1998-03-04 | — | — | EP | disclosed |
| EP-0412387-B1 | Diarylacetylenes, their process and use | BASF AG (DE) | 1993-11-24 | — | — | EP | disclosed |
| US-5256694-A | For skin disorders; carcinomas | BASF AKTIENGESELLSCHAFT (DE) | 1993-10-26 | — | — | US | disclosed |
| US-5126371-A | Precancerous skin conditions, acne, psoriasis | BASF AKTEINGESELLSCHAFT (DE) | 1992-06-30 | — | — | US | disclosed |
| US-5087637-A | Skin disorders | BASF AKTIENGESELLSCHAFT (DE) | 1992-02-11 | — | — | US | disclosed |
| US-4994489-A | Ester derivatives of diarylacetylenes, their compositions and their use in acne treatment | BASF AKTIENGESELLSCHAFT | 1991-02-19 | — | — | US | disclosed |
| EP-0412387-A2 | Diarylacetylenes, their process and use | BASF Aktiengesellschaft (DE) | 1991-02-13 | — | — | EP | disclosed |
| EP-0176034-B1 | DIARYL ACETYLENES, THEIR PREPARATION AND USE | BASF Aktiengesellschaft (DE) | 1989-08-30 | — | — | EP | disclosed |
| US-4806558-A | Diarylacetylenes and their use in treating acne | BASF AKTIENGESELLSCHAFT (DE) | 1989-02-21 | — | — | US | disclosed |
| EP-0176034-A2 | Diaryl acetylenes, their preparation and use | BASF Aktiengesellschaft (DE) | 1986-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108533-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | PNP, TYMP, MTAP | FDPS 930/4885LAP3 2319/4885S1PR2 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.